Table 2 Genetic alterations in advanced/metastatic or recurrent GIST patients who received TKI treatment
Genotype | c-KIT exon 9 | c-KIT exon 11 | c-KIT exon 13 | c-KIT exon 17 | PDGFRA | Wild-type c-KIT/PDGFRA | overall | P * value |
|---|---|---|---|---|---|---|---|---|
Sex | 18 | 136 | 1 | 2 | 3 | 17 | 177 | 0.0215 |
    men | 13(72.2%) | 71(52.2%) | 1(100.0%) | 2 (100.0%) | 3 (100.0%) | 14 (82.4%) | 104 (58.8%) |  |
    women | 5 (27.8%) | 65 (47.8%) | 0 | 0 | 0 | 3 (17.6%) | 73 (41.2%) |  |
Primary site | 18 | 136 | 1 | 2 | 3 | 17 | 177 | 0.01 |
    stomach | 1 (5.6%) | 55 (40.4%) | 1 (100.0%) | 2 (100.0%) | 2 (66.7%) | 4 (23.5%) | 65 (36.7%) |  |
    nonstomach | 17 (94.4%) | 81 (59.6%) | 0 | 0 | 1 (33.3%) | 13 (76.5%) | 112 (63.3%) |  |
ECOG PS | 12 | 75 | 1 | 0 | 1 | 9 | 98 | 0.5927 |
    0 | 4 (33.3%) | 34 (45.3%) | 0 | 0 | 0 | 5 (55.6%) | 43 (43.9%) |  |
    1 | 8 (66.7%) | 33 (44.0%) | 1 (100.0%) | 0 | 1 (100.0%) | 3 (33.3%) | 46 (46.9%) |  |
    2 | 0 | 6 (8.0%) | 0 | 0 | 0 | 0 | 6 (6.1%) |  |
    3 | 0 | 2 (2.7%) | 0 | 0 | 0 | 1 (11.1%) | 3 (3.1%) |  |
Age | 18 | 136 | 1 | 2 | 3 | 17 | 177 | 0.0205 |
    < 60 | 15 (83.3%) | 74 (54.4%) | 0 | 2 (100.0%) | 1 (33.3%) | 13 (76.5%) | 105 (59.3%) |  |
    >  = 60 | 3 (16.7%) | 62 (45.6%) | 1 (100.0%) | 0 | 2 (66.7%) | 4 (23.5%) | 72 (40.7%) |  |